Cartesian Therapeutics

Cartesian Therapeutics Enterprise Value

The Enterprise Value (EV) of Cartesian Therapeutics (RNAC) as of Oct 17, 2026 is 48.56 M USD. In the previous year, Enterprise Value (EV) was -43.07 M USD — a change of -212.75% (higher).

Enterprise Value

48.56 MUSD

YoY

-212.75%

Last updated:

Enterprise Value (EV) of Cartesian Therapeutics is 2025 48.56 M USD. Enterprise Value (EV) of Cartesian Therapeutics was 2024 -43.07 M USD. It decreases by -212.75% higher compared to the previous year.

The Cartesian Therapeutics Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
153.53 M USD
Jan 1, 2019
98.28 M USD
Jan 1, 2020
55.65 M USD
Jan 1, 2021
67.12 M USD
Jan 1, 2022
61.20 M USD
Jan 1, 2023
92.63 M USD
Jan 1, 2024
-43.07 M USD
Jan 1, 2025
48.56 M USD
The Cartesian Therapeutics Enterprise Value history
YEAREnterprise ValueYoY
48.56 MUSD-212.75%
-43.07 MUSD-146.49%
92.63 MUSD+51.35%
61.20 MUSD-8.82%
67.12 MUSD+20.61%
55.65 MUSD-43.37%
98.28 MUSD-35.99%
153.53 MUSD+63.42%
93.95 MUSD-3.59%
97.45 MUSD-32.77%
144.94 MUSD-9.61%
160.35 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cartesian Therapeutics Stock analysis

What does Cartesian Therapeutics do? Cartesian Therapeutics Inc, trading under the ticker RNAC, is a biotechnology company based in Watertown, United States. The company has 75 employees and went public via an IPO on June 22, 2016. Cartesian Therapeutics operates within the Health Care sector, specifically in the Biotechnology industry. The company's website is https://selectabio.com/. Cartesian Therapeutics focuses on developing therapeutic solutions, though specific product names or clinical stage details are not provided in the available information. The company's headquarters are located in Watertown, and it is engaged in research and development activities typical of a biopharmaceutical firm. Cartesian Therapeutics is identified by its ISIN number US8162123025. The company's activities are centered around advancing biotechnology for healthcare applications, with a focus on innovative therapeutic approaches. The company's operational scope and specific research areas are not detailed beyond the general biotechnology sector focus. Cartesian Therapeutics is a clinical-stage biopharmaceutical company, though the exact stage of clinical development for any specific therapy is not specified in the provided data. The company's website serves as a primary source of information for further details on its operations and developments. Cartesian Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cartesian Therapeutics stock

Enterprise Value (EV) of Cartesian Therapeutics is 48.56 M USD in 2025.

Enterprise Value (EV) of Cartesian Therapeutics changed from -43.07 M USD to 48.56 M USD, representing a -212.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Cartesian Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Cartesian Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cartesian Therapeutics

All Key Metrics — Cartesian Therapeutics